Information Provided By:
Fly News Breaks for October 9, 2018
ATRC
Oct 9, 2018 | 07:11 EDT
Canaccord analyst Jason Mills raised his price target on AtriCure to $40 following the successful secondary offering of shares and strong preliminary Q3 results. The funds raised are earmarked to pay down debt, pursue strategic acquisitions, and bolster working capital, noted Mills, who reiterated his Buy rating on AtriCure shares.
News For ATRC From the Last 2 Days
ATRC
ATRC
Apr 23, 2024 | 06:16 EDT
Oppenheimer analyst Suraj Kalia upgraded AtriCure to Outperform from Perform with a $32 price target.
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.